(S)-2-(pyridin-2-yl)but-3-yn-2-ol | 1042989-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-2-(pyridin-2-yl)but-3-yn-2-ol
• 英文别名: (2S)-2-(2-pyridyl)but-3-yn-2-ol；(2S)-2-pyridin-2-ylbut-3-yn-2-ol
• CAS: 1042989-14-9
• 化学式: C₉H₉NO
• 分子量: 147.177
• InChiKey: SNKQUAATTWNZCV-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  10-bromo-9-fluoro-N³-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide 、 (S)-2-(pyridin-2-yl)but-3-yn-2-ol 以to afford 7.7 mg (9%) of 9-fluoro-10-[(3S)-3-hydroxy-3-(2-pyridyl)but-1-ynyl]-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide的产率得到9-fluoro-10-[(3S)-3-hydroxy-3-(2-pyridyl)but-1-ynyl]-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide
  参考文献：
  名称：

  Tricyclic compounds and methods of use therefor

  摘要：

  本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。式I的化合物及其制备的药物组合物在治疗疾病和障碍方面是有用的，其中观察到NF-kB信号的不良或过度激活。

  公开号：

  US09034866B2
• 作为产物：
  描述：

  (R,S)-2-(pyridin-2-yl)but-3-yn-2-yl acetate 在 EstA₄ 作用下， 生成 (S)-2-(pyridin-2-yl)but-3-yn-2-ol
  参考文献：
  名称：

  Identification of novel esterases for the synthesis of sterically demanding chiral alcohols by sequence-structure guided genome mining

  摘要：

  Six esterases isolated from sequence and structure-guided genome mining approaches were evaluated for the kinetic resolution of secondary and tertiary alcohols that find application in the fine chemical and pharmaceutical industries. Activity and enantioselectivity with E-values of up to 24 were determined towards a range of sterically demanding tertiary alcohol esters. Excellent enantioselectivity (E > 100) was also achieved in the hydrolysis of a less challenging secondary alcohol ester, menthyl acetate. These results highlight that these approaches can be used for the identification of novel esterases applicable to the preparation of commercially desirable alcohols. (C) 2011 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcatb.2011.02.009

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• Tricyclic compounds and methods of use therefor
  申请人：Genentech, Inc.

  公开号：US09034866B2

  公开（公告）日：2015-05-19

  The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。式I的化合物及其制备的药物组合物在治疗疾病和障碍方面是有用的，其中观察到NF-kB信号的不良或过度激活。
• Small molecule inhibitors of NF-κB inducing kinase
  申请人：Janssen Pharmaceutica NV

  公开号：US11254673B2

  公开（公告）日：2022-02-22

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制 NIK 的化合物、含有此类化合物的药物组合物以及使用方法。根据设想，这些化合物和药物组合物可用于预防或治疗癌症（如 B 细胞恶性肿瘤，包括白血病、淋巴瘤和骨髓瘤）、炎症性疾病、自身免疫性疾病、免疫性皮肤病（如掌跖脓疱病和化脓性扁桃体炎）以及代谢性疾病（如肥胖症和糖尿病）等疾病。
• Characterization of a novel esterase isolated from intertidal flat metagenome and its tertiary alcohols synthesis
  作者：Ki-Hoon Oh、Giang-Son Nguyen、Eun-Young Kim、Robert Kourist、Uwe Bornscheuer、Tae-Kwang Oh、Jung-Hoon Yoon

  DOI：10.1016/j.molcatb.2012.04.015

  日期：2012.8

  A gene coding for an esterase (EstEH112) was isolated from metagenome originated from Korean intertidal flat sediment. The putative esterase gene encoded a 340 amino acids protein with characteristic residues of lipolytic enzymes such as a conserved pentapeptide (GXSXG), the typical catalytic S-D-H triad, and a GGG(A)X-motif in the oxyanion hole near the active site similar to the hormone sensitive lipase (HSL) family. p-Nitrophenyl butyrate was the best substrate for the enzyme among the other p-nitrophenyl esters investigated. The apparent optimal temperature and pH for EstEH112 was 35 C and at pH 8.0, respectively. EstEH112 efficiently catalyzed the hydrolysis of various large tertiary alcohol esters. These characteristics of EstEH112 make it a potential candidate for application in biocatalysis. (C) 2012 Elsevier B.V. All rights reserved.
• SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
  申请人：Janssen Pharmaceutica NV

  公开号：US20210300918A1

  公开（公告）日：2021-09-30

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.